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OBJECTIVE—Insulin analogs are increasingly used in patients with type 2 diabetes. We
compared the effect of basal, biphasic, prandial, and basal-bolus insulin regimens with insulin
analogs to reach the hemoglobin A1c (HbA1c)t a r g e to f,7% in people with type 2 diabetes.
RESEARCH DESIGN AND METHODS—We conducted an electronic search for ran-
domized controlled trials (RCTs) involving insulin analogs. RCTs were included if they lasted at
least 12 weeks, reported the proportion of diabetic patients reaching the HbA1c target of ,7%
(primary outcome), and the number of patients in any arm was .30.
RESULTS—Wefound16RCTs,with20comparisonsand7,759patients.Agreaterproportion
of patients achieved the HbA1c goal of ,7% with both biphasic (odds ratio 1.88 [95% CI 1.38–
2.55]) and prandial (2.07 [1.16–3.69]) insulin compared with basal insulin; this was associated
for biphasic insulin with greater hypoglycemia (event/patient/30 days, mean difference, 0.34
[range0–0.69])andweightgaininkg(1.0kg[0.28–1.73]).Comparedwithbiphasicinsulin,the
basal-bolusregimenwasassociatedwithagreaterchancetoreachtheHbA1cgoal(oddsratio1.75
[95% CI 1.11–2.77]), with no greater hypoglycemia or weight gain. The effect of insulin analogs
on long-term diabetes complications is still lacking.
CONCLUSIONS—Agreaterproportionoftype2diabeticpatientscanachievetheHbA1cgoal
,7%withbiphasic or prandialinsulincomparedwithbasalinsulin;inabsoluteterms,thebasal-
bolus regimen was best for the attainment of the HbA1c goal.
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T
ype 2 diabetes is a complex and
progressive disease that has reached
epidemic proportions worldwide
(1). In the U.S., diabetes is the third cause
of death for women and the fourth for
men (2). Tight glycemic control, to main-
tain a hemoglobin A1c (HbA1c) concen-
tration of ,7%, is recommended for all
nonpregnant adults with diabetes to min-
imize the risk of long-term microvascular
(retinopathy, nephropathy, neuropathy)
complications(3,4).TheHbA1cgoaliscur-
rently achieved in ;50% of patients with
type 2 diabetes, at least in selected popu-
lations (3).
Although traditionally used as a ﬁnal
treatment option, insulin has been re-
cently recommended by the American
Diabetes Association (ADA) and the Eu-
ropean Association for the Study of Di-
abetes (EASD) as a third-line treatment
after diet, exercise, and metformin fail to
reach or maintain an HbA1c of ,7% (5).
According to the National Health Inter-
view Survey, 28% of patients with type
2 diabetes are using insulin, alone (16%)
or combined with oral antidiabetic drugs
(12%) (6). The choice of an initial insulin
regimen for people with type 2 diabetes,
in whom oral drugs have failed, may be a
difﬁcult one because hypoglycemia and
the fear of developing hypoglycemia re-
main substantial barriers to the initiation
and optimal use of insulin (7).
Insulin analogs are modiﬁed human
insulins developed to address the limita-
tions of human insulin preparations to
replicate the pattern of basal and post-
prandial endogenous secretion of insulin
(8). Conversion of the insulin market to
analogs, estimated to be 40% 45% in
2005, is projected to reach saturation
within2010(9).Systematicreviewsofin-
sulin analogs have been published previ-
ously (10–13). Compared with human
insulins, rapid, biphasic (premixed), and
basal (long-acting) insulin analogs offer
some beneﬁt in better glycemic control
and reduced hypoglycemia (10,12,13).
However, we did not identify any reviews
that evaluated the proportion of patients
with type 2 diabetes achieving the HbA1c
target ,7% with insulin analogs. In this
article, we performed a meta-analysis of
the randomized controlled trials (RCTs)
that compared the effect of different insu-
lin regimens based on insulin analogs.
RESEARCH DESIGN AND
METHODS—We followed the Pre-
ferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA)
checklist for reporting systematic reviews
and meta-analyses (14).
Data sources
We searched MEDLINE (1966 to January
2010), EMBASE (1980 to January 2010),
the Cochrane Central Register of Con-
trolled Trials, and CINAHL from incep-
tion to January 2010. The main search
concepts were type 2 diabetes, hemoglo-
bin A1c, long-acting insulin analogs,
short-acting insulin analogs, biphasic in-
sulin analogs, glargine, detemir, neutral
protamine lispro, lispro, aspart, glulisine,
randomized controlled trials, and clinical
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Giugliano and Associatestrials. We also reviewed reference lists of
included articles, the US Food and Drug
Administration and European Medicines
Agency Web sites for the insulin analogs,
as well as Web sites of public registries
of clinical trials (ClinicalTrials.gov and
ClinicalStudyResults.org).
Study selection
We included RCTs if 1)p a t i e n t sa g e d
.18 years with a diagnosis of type 2 di-
abetes,asdeﬁnedbycriteriacurrentatthe
time of the trial (15) were included; 2)
different insulin regimens (basal, bi-
phasic, prandial or basal-bolus) using in-
sulin analogs were evaluated; and 3)t h e
proportion of diabetic patients reaching
the HbA1c goal of #7% was reported.
We included crossover trials with at least
12weeksoffollow-upbeforeandafterthe
crossover phase. The search had no lan-
guage restriction; however, we excluded
reviews, editorials, comments, letters,
and abstracts. Trials were rejected if the
intervention time was ,3 months, the
number of patients in any arm was ,30
patients, or comparisons were between
insulin analogs and conventional insulins
within the same or different regimens.
Quality assessment
Two investigators (D.G. and K.E.) identi-
ﬁed relevant publications and abstracted
the data, and any disagreements were
resolved by consensus. Methodologic
quality was scored using criteria set out
by Jadad et al. (16). This 5-point quality
scale includes points for randomization
(described as randomized, 1 point; table
ofrandomnumbersorcomputer-generated
randomization,additional1point),double-
blind (described as double-blind, 1 point;
use of masking such as identical placebo,
additional 1 point), and follow-up (the
numbers and reasons for withdrawal in
each group are stated; 1 point) in the re-
port of an RCT. We gave an additional
point if the analysis was by intention-to-
treat. We considered scores of #2 as low
quality and a score of $3 as high quality
because none of the studies were double-
blinded, due to the visibly different prop-
erties of the comparators.
Insulin regimens
We compared four insulin regimens:
c the biphasic regimen consisted of the
biphasic (premixed) insulin analogs lis-
pro 25/75, lispro 50/50, aspart 30/70,
aspart 50/50, and aspart 70/30, with the
numbers denoting the percentage of the
rapid-acting/the long-acting compo-
nent;
c the basal regimen consisted of basal
insulin analogs comprising the long-
acting insulins glargine, detemir, and
lispro/neutral protamine lispro;
c the prandial regimen consisted of prandial
insulin analogs, comprising short-acting
insulins lispro, aspart, and glulisine; and
c thebasal-bolus regimen consisted ofany
combination of prandial and basal in-
sulin analogs.
No studies comparing basal or pran-
dial with basal-bolus regimens met the
inclusion criteria.
Data synthesis and analysis
The proportion of patients with HbA1c
,7% at the end of treatment was the pri-
maryoutcome.Secondaryoutcomeswere
hypoglycemic events and weight gain.
Statistically, binomial proportion lacks
consensusoverthe calculationofthe con-
ﬁdence intervals. We transformed the
proportions into a quantity suitable for
the usual ﬁxed and random-effects sum-
maries (the Freeman-Tukey variant of the
arc sine square root transformed propor-
tion) (17). The pooled proportion is cal-
culated as a back-transformation of the
weighted mean of the transformed pro-
portions, using inverse arc sine variance
weights for the ﬁxed-effects model and
DerSimonian-Laird weights (18) for the
random-effects model.
Denominators used for calculating
theresponserateoneachtreatmentgroup
were those reported within original stud-
ies as eligible patients coming from ran-
domization. The association between
exposure (treatments) and outcome (pro-
portions of patients with HbA1c ,7%)
was measured by the odds ratio (OR).
When the OR and 95% CIs were avail-
able, we transformed them into logOR
and calculated the corresponding vari-
anceandstandarderrorusingtheformula
proposed by Greenland (19). When the
OR was not directly available from the
article, we calculated it from tabular data
and used the Woolf formula to evaluate
the standard error of the logOR (20). If
tabular data were not given and only re-
sponse rate was available, the number of
responses was calculated by multiplying
the response rate by the number of ran-
domized/eligible patients. Pooled OR
with 95% CI was estimated, pooling the
study-speciﬁc estimates by random-effects
models ﬁtted using SAS (PROC MIXED)
software (SAS Institute) with maximum
likelihood estimate. These models pro-
vided estimates adjusted for the heteroge-
neity between studies and the correlation
within studies given by the randomized
studies with more than two groups. That
is a conservative approach because it raises
the variability caused by the correlation
within study, providing, as a result, wider
and more reliable CIs.
Heterogeneity of the effect across
studies was assessed by Q
2 statistics,
which is distributed as x
2 statistics. A
value of P , 0.10 was used to indicate
lack of homogeneity among effects. I
2 sta-
tistics were provided to quantify the per-
centage of total variation across studies
that was attributable to heterogeneity
rather than to chance (21). A value
.50%representedsubstantialvariability.
The method of Macaskill et al. (22) was
usedforassessingpublicationbias.Itcon-
sistsofafunnel-plotregressionoflog(RR)
or log(OR) on the sample size, weighted
by the inverse of the pooled variance.
For hypoglycemic events and weight
gain, we recorded the mean difference
betweengroups,alongwithitsmeasureof
dispersion. If no measure of dispersion
was reported for the between-group dif-
ference, we conservatively estimated it by
the worst ratio between mean and stan-
dard deviation among the available stud-
ies. If a trial reported the number of
episodes in each group or reported an




RESULTS—We identiﬁed 2,650 cita-
tions,ofwhichwereviewed126;ofthese,
16 (23–38) performed comparisons be-
tween different insulin regimens and
were included in the meta-analysis
(Supplementary Fig. 1). Most trials were
multinationaland sponsored by industry.
All studies were RCTs (Table 1): among
these, 13 were parallel group and 3
(23,24,27) were crossover. All studies
were of open-label design. Trial duration
was 3 to 36 months. The trials enrolled a
total of 7,759 patients (range, 60–2,091).
Patients were a mean age of 58.2 years,
with slight prevalence of male sex
(55.6%). The study population had a me-
dian HbA1c level of 8.6% (interquartile
range 8.4–9.1%).
Nine trials enrolled insulin-naïve
patients (23,25,27–29,31,32,35,37),
six enrolled insulin-treated patients
(24,30,33,34,36,38), and one enrolled
mixed patients (26). The median score
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Insulin analogs and HbA1c targetFigure 1—Biphasic versus basal: A: Outcome, proportion (%) of patients with HbA1c ,7%. B: Change in incidence of hypoglycemia. C: Change in
weight. N = number of patients in each arm. *Mixed-effects model: estimates adjusted for the correlation within studies and heterogeneity between
studies; ^sensitivity analysis.
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Giugliano and Associatesof methodologic quality was 2.5 (inter-
quartile range 2–4). Ten trials (25,29–
31,33–38) used a predeﬁned titration
step of insulin doses. Eleven trials had a
clear intention-to-treat analysis (24–
26,28–31,34–38). Eleven trials (23–
27,29–31,33,35,37) adopted combined
treatment regimens of oral drugs plus in-
sulin (whichever regimen); the most-
represented oral drugs were metformin, a
sulfonylurea, or a glitazone.
Biphasic versus basal
Ten trials (23–30,35,37) were eligible.
Most included insulin-naïve patients
(23,25,27–30,35,37) and adopted com-
bined treatment regimens of oral drugs
plus insulin (23–27,29,30,35,37). Com-
pared with basal insulin, patients treated
withbiphasicinsulinhadagreaterchance
to reachthe HbA1c goalof ,7%(OR1.88
[95% CI 1.38–2.55]; Fig. 1A). There was
noevidenceofpublicationbias(P=0.15).
Heterogeneity was high (I
2 =6 8 % )b u t
diffuse. Compared with basal insulin, bi-
phasic insulin was associated with a sig-
niﬁcant increase in hypoglycemic events
(0.34 mean events/patient/30 days), but
signiﬁcant heterogeneity was observed
(I
2 = 64.9%). Exclusion of one trial (27)
with the highest hypoglycemic rate com-
pletely eliminated heterogeneity (I
2 =0 %;
Fig. 1B). Biphasic insulin was also associ-
ated with greater weight gain (mean dif-
ference, 1 kg [95% CI 0.28–1.73]) with
high heterogeneity (I
2 = 85.2%; Fig. 1C).
Final median (interquartile range) insulin
dose was 0.5 units/kg (0.39–0.62) for bi-
phasic and 0.41 units/kg (0.29–0.55) for
basal insulin (P =0 . 1 6 ) .
Biphasic versus prandial
Three trials (28,29,32) were eligible. All
trials included insulin-naïve patients. No
difference betweentreatmentswasshown
for achievement of HbA1c goal (OR 1.04
[95% CI 0.37–2.92]; Supplementary Fig.
2). There was no evidence of publication
bias (P = 0.39). There was no mean (95%
CI) difference in the incidence of hypo-
glycemia events/patient/30 days (20.15
[20.57 to 0.27]) or weight gain (0.1 kg
[20.71 to 1.9]) between the two regi-
mens. One trial did not report insulin
dose (32). For the remaining two trials,
no difference in daily insulin dose was
observed between the two regimens.
Prandial versus basal
Four studies (28,29,31,36) were eligible.
Comparedwithbasalinsulin,prandialin-
sulin was associated with a nonsigniﬁcant
chanceofachievementtheHbA1cgoal(OR
1.58 [95% CI 0.77–3.23]; Supplementary
Fig. 3). An evidence of publication was
detected (P = 0.07). A sensitivity analysis
excluding one trial (36) gave signiﬁcant
results (OR 2.07 [95% CI 1.16–3.69])
with no evidence of heterogeneity (I
2 =
0%) or publication bias (P = 0.37). Com-
pared with basal insulin, prandial insulin
was associated with a nonsigniﬁcant
increase in the incidence of hypoglycemia,
with high heterogeneity (I
2 = 99.7%),
which persisted elevated (I
2 =9 7 . 7 % )a f t e r
exclusion of one trial. Prandial insulin was
also associated with a greater weight in-
crease of borderline signiﬁcance. Final me-
dian (interquartile range) insulin dose was
0.56 units/kg (0.51–0.60) for prandial and
0.49 units/kg (0.46–0.51) for basal insulin
(P =0 . 0 6 ) .
Biphasic versus basal-bolus
Threestudies(33,34,38)wereeligible.All
trials included patients who were not
insulin-naïve. The inclusion of the 3-
year extension of the Treating to Target
in Type 2 Diabetes (4-T) trial (38) in the
present comparison was justiﬁed by the
switching of 73.7% of the former original
prandial and 81.5% of the basal regimen
to a basal-bolus regimen. Compared with
biphasic insulin, patients treated with a
basal-bolus regimen had a higher chance
toreachtheHbA1cgoal(OR,1.75[95%CI
1.11–2.77]), with no evidence of hetero-
geneity (I
2 = 0%; Fig. 2). There was no
evidence of publication bias (P = 0.78).
There was no difference in incidence of
hypoglycemia and weight gain between
the two regimens. Final median (inter-
quartile range) insulin dose was 0.78
units/kg (0.66–1.09) for biphasic insulin
and 0.97 units/kg (0.90–1.29) for the
basal-bolus regimen (P = 0.40).
CONCLUSIONS—T h eu l t i m a t eg o a l
of treatment of diabetes is improvement
inmicrovascularandmacrovascularcom-
plications,anddeath.Mosttrialsincluded
in this analysis were not speciﬁcally de-
signed to evaluate these clinical out-
comes. Although not ideal, HbA1c is the
most-used intermediate outcome to op-
timize glycemic control in a clinical set-
ting. The ADA position statement on
standards of medical care in diabetes (4)
insists on the optimal HbA1c target of
,7% for most nonpregnant adults,
stressing the evidence that microvascular
complications are better mitigated with
this goal with respect to macrovascular
complications (level of evidence A vs. B,
respectively).
We found that biphasic and prandial
insulin were both associated with a
greater proportion of type 2 diabetic
patients achieving the HbA1c goal of ,7%
compared with basal insulin. This effect
was consistent across pooled trials. The
basal-bolus regimen was better than bi-
phasic, and in absolute terms, was the
best regimen for the attainment of the
Figure 1—Continued.
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Insulin analogs and HbA1c targetHbA1c goal. Ultimately, the proportion of
patients with a HbA1c goal of ,7% using
the basal-bolus regimen was 63.5%. The
effect of the different insulin regimens on
hypoglycemia was quite similar across
different comparisons, with the exception
of a greater event rate with the biphasic
compared with basal insulin. Biphasic
and prandial insulin were both associated
with greater weight gain compared with
basal insulin, and this effect was also con-
sistent across pooled trials.
Biphasic insulin is less effective than
basal insulin in decreasing fasting glucose
levels but is more effective in decreasing
Figure 2—Biphasic versus basal-bolus. A: Outcome, proportion (%) of patients with HbA1c ,7%. B: Change in incidence of hypoglycemia.
C: Change in weight. N = number of patients in each arm. *Mixed-effects model: estimates adjusted for the correlation within studies and het-
erogeneity between studies.
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analyses showed biphasic insulin was as-
sociated with more hypoglycemia than
basal insulin (;0.34 mean events/pa-
tient/30 days). These data are consistent
with previous analyses (9,10) showing
that biphasic insulin is more likely to
cause hypoglycemia than basal insulin,
although in one study (10) the effect of
the different insulin regimens could not
be pooled in a meta-analysis. The inci-
dence of hypoglycemia was similar
between the other comparisons. The
overall median incidence of hypoglyce-
mia across all the comparisons was gen-
erally low, at 0.4 events/patient/30 days
(range, 0–4.71 [interquartile range 0.3–
1.0]). Biphasic and prandial insulin both
caused more weight gain than basal insu-
lin;however,weightgainwaslimited,at1
and 1.94 kg, respectively. No difference
in weight gain was found between bi-
phasic versus prandial insulin or biphasic
insulin versus the basal-bolus regimen.
The reduced frequency of insulin
injections and glucose monitoring, asso-
ciated with its inherent simplicity, has led
to thebasal insulinregimen becoming the
ﬁrst option in initiating insulin therapy in
recentguidelines(5).Althoughsuccessful
for many patients, at least 60% of patients
taking basil insulin were not able to reach
the HbA1c target. When the HbA1c goal is
notattaineddespitesuccessfulbasalinsulin
dose titration, or when titration is limited
by hypoglycemia, treatment is generally
intensiﬁed by addition of prandial or bi-
phasic insulin. According to our analysis,
this escalation in insulin regimens from
the simple basal to the complex basal-
bolus may result in a further gain in the
proportion of type 2 diabetic patients at-
taining the HbA1c goal (63.5% with the
basal-bolus regimen), which still leaves
;33% of patients not at the target goal.
Thisstudyhaslimitations.Thedegree
of heterogeneity was high for some com-
parisons, although results in most cases
werequalitativelysimilaracrossstudiesin
directions of the results. Moreover, sen-
sitivity analysis eliminated heterogeneity
in most cases. In addition, there was no
evidence of publications bias.
Most studies had a short follow-up,
and ﬁrm conclusions cannot be draw
about the long-term comparative effec-
tiveness of the various regimens. Any
improvements seen in HbA1c in these
short-term trials may not be sustained
over a longer period, although studies
with longer follow-up gave similar re-
sults. Only one long-term study (mean
patient participation after randomization
was 963 days) was speciﬁcally designed
for assessing cardiovascular outcomes in
survivors to a ﬁrst myocardial infarction
comparing basal with biphasic insulin, but
the study was stopped for lack of efﬁcacy
(36). Other long-term trials reported clini-
cal outcomes as adverse events.
In conclusion, our analysis of 7,759
type 2 diabetic patients using insulin
analogs indicates that the HbA1c target
,7% can be achieved in 35 to 63.5%,
depending on the particular insulin regi-
men. Basal insulin is associated with a
lower proportion of diabetic patients at
targetcomparedwithprandialorbiphasic
insulin, but with less hypoglycemia and
weight gain compared with biphasic in-
sulin. The best achievement rate is ob-
tained with a basal-bolus regimen
compared with biphasic insulin, without
f u r t h e rr i s ko fh y p o g l y c e m i ao rw e i g h t
gain. More studies are needed to under-
stand better the effect of insulin analogs
on long-term diabetes complications.
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